Strongbridge Biopharma PLC SBBP
We take great care to ensure that the data presented and summarized in this overview for Strongbridge Biopharma plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SBBP
Top Purchases
Top Sells
About SBBP
Insider Transactions at SBBP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 05
2021
|
Cdk Associates, L.L.C. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
8,060,682
-100.0%
|
-
|
|
Oct 05
2021
|
Stephen J Long Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
117,793
-100.0%
|
-
|
|
Oct 05
2021
|
David N Gill Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
78,058
-100.0%
|
-
|
|
Oct 05
2021
|
Garheng Kong Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
63,993
-100.0%
|
-
|
|
Oct 05
2021
|
Jeffrey W Sherman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
64,258
-100.0%
|
-
|
|
Oct 05
2021
|
Marten Steen Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
64,151
-100.0%
|
-
|
|
Oct 05
2021
|
Hilde H Steineger Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
64,258
-100.0%
|
-
|
|
Oct 05
2021
|
John Johnson Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
610,092
-100.0%
|
-
|
|
Oct 05
2021
|
Fredric J. Cohen Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
160,408
-50.0%
|
-
|
|
Oct 05
2021
|
Richard S Kollender President and CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
234,229
-100.0%
|
-
|
|
Oct 05
2021
|
Scott L. Wilhoit Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
109,510
-100.0%
|
-
|
|
Oct 01
2021
|
David N Gill Director |
SELL
Payment of exercise price or tax liability
|
Direct |
17,763
-18.54%
|
$35,526
$2.06 P/Share
|
|
Oct 01
2021
|
Garheng Kong Director |
SELL
Payment of exercise price or tax liability
|
Direct |
17,763
-21.73%
|
$35,526
$2.06 P/Share
|
|
Oct 01
2021
|
Jeffrey W Sherman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
17,763
-21.66%
|
$35,526
$2.06 P/Share
|
|
Oct 01
2021
|
Hilde H Steineger Director |
SELL
Payment of exercise price or tax liability
|
Direct |
17,763
-21.66%
|
$35,526
$2.06 P/Share
|
|
Oct 01
2021
|
John Johnson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
334,868
-35.44%
|
$669,736
$2.06 P/Share
|
|
Oct 01
2021
|
Marten Steen Director |
SELL
Payment of exercise price or tax liability
|
Indirect |
17,763
-21.68%
|
$35,526
$2.06 P/Share
|
|
Oct 01
2021
|
Fredric J. Cohen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
51,548
-24.32%
|
$103,096
$2.06 P/Share
|
|
Oct 01
2021
|
Richard S Kollender President and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
64,791
-21.67%
|
$129,582
$2.06 P/Share
|
|
Oct 01
2021
|
Stephen J Long Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
49,307
-29.51%
|
$98,614
$2.06 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders